Michael Burgess: “We must consider the potential impact that this requirement could have on the industry.”

I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.

I led a letter to the FDA asking them to reclassify naloxone to where you could get it without a prescription.

I never expected that CMMI was actually going to deliver the cost savings that was promised.

I thank the gentleman for yielding additional time. However, one-sided pressure by the White House is not the way to ensure that end. Mr. Speaker, I urge passage of this rule from our committee, and I urge passage of the underlying…